IMGN151 + Carboplatin + Bevacizumab + Olaparib
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gynecologic Cancers
Conditions
Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
Trial Timeline
Jul 30, 2025 → Feb 1, 2028
NCT ID
NCT07024784About IMGN151 + Carboplatin + Bevacizumab + Olaparib
IMGN151 + Carboplatin + Bevacizumab + Olaparib is a phase 2 stage product being developed by AbbVie for Gynecologic Cancers. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07024784. Target conditions include Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07024784 | Phase 2 | Recruiting |
Competing Products
13 competing products in Gynecologic Cancers
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 1 | 33 |
| Atezolizumab + Rucaparib | Roche | Phase 1 | 33 |
| Vigil + Atezolizumab | Roche | Phase 2 | 52 |
| darbepoetin alfa + recombinant human erythropoietin (rHuEPO) | Amgen | Phase 2 | 51 |
| Oral apixaban + Subcutaneous enoxaparin | Bristol Myers Squibb | Phase 2 | 51 |
| AK112 | Akeso | Phase 2 | 51 |
| Ciprofol + Propofol | Haisco Pharmaceutical Group | Phase 3 | 74 |
| Floseal | Baxter | Phase 3 | 74 |
| FloSeal application | Baxter | Pre-clinical | 20 |
| IPH2201 | Innate Pharma | Phase 1 | 25 |
| Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2) | Alaunos Therapeutics | Phase 1/2 | 33 |
| Neoantigen specific TCR-T cell drug product | Alaunos Therapeutics | Pre-clinical | 15 |